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Abstract 
Since extracellular vesicles (EVs) were discovered in 1983 in sheep reticulocytes samples, they 
have gradually attracted scientific attention and become a topic of great interest in the life 
sciences field. EVs are small membrane particles, released by virtually every cell that carries a 
variety of functional molecules. Their main function is to deliver messages to the surrounding 
area in both physiological and pathological conditions. Initially, they were thought to be either 
cell debris, signs of cell death, or unspecific structures. However, accumulating evidence 
support a theory that EVs are a universal mechanism of communication. Thanks to their 
biological characteristics and functions, EVs are likely to represent a promising strategy for 
obtaining pathogen information, identifying therapeutic targets and selecting specific 
biomarkers for a variety of diseases, such as autoimmune diseases. 
In this review, we provide a brief overview of recent progress in the study of the biology and 
functions of EVs. We also discuss their roles in diagnosis and therapy, with particular emphasis 
on autoimmune diseases. 
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Introduction 
Extracellular vesicles (EVs) are broadly classified 
in three sub-classes, depending on their biogenesis 
and size, exosomes (10-100nm); microvesicles (MVs), 
also called ectosomes, (100-1000nm); apoptotic bodies 
(1000-5000 nm) [1]. However, even if this 
nomenclature is extensively used, the classification of 
these heterogeneous populations of EVs is still a 
matter of debate [2]. Our initial understanding of EVs 
originated from exosomes found in sheep 
reticulocytes in 1983 [3]. EVs represent a direct means 
of cellular communication [1]. They thus play an 
important role in the development and regulation of 
many biological processes [4]. They carry proteins, 
DNA and various RNAs: mRNAs, miRNAs, long 
non-coding RNAs (lncRNAs), circular RNAs 
(circRNAs), all involved in intracellular signal 
transduction [5]. New research evidence suggests that 
mitochondria may also be contained in EVs, and that 
these mitochondria are capable of inducing epigenetic 
modifications of target cells in target organs, such as 
mesenchymal stem cells (MSCs) altering the 
macrophage phenotype by EVs-mediated 
mitochondrial transfer [6]. To induce an effect, EVs 
must interact with target cells, either directly with the 
plasma or with the endosomal membrane after 









EVs uptake have been proposed [7]. 
Given that, theoretically, every cell in the body 
releases EVs and that in pathological conditions their 
amount may increase, they represent an excellent 
biomarker for several diseases [5]. In fact, thanks to 
their properties, EVs can be detected in many 
different biological fluids such as blood, saliva, urine, 
semen, bile, cerebrospinal fluid (CSF), amniotic fluid, 
ascites and breast milk [8-10]. Finally, thanks to their 
biological characteristics, the idea of using EVs as a 
therapeutic delivery vehicle in many applications has 
recently emerged [11]. Indeed, the ability to deliver 
molecules in different biological districts hardly 
accessible such as central nervous system (CNS), 
without showing immunogenicity, candidates EVs as 
future therapy. So far, several approaches using EVs 
as therapy have been proposed [12-15], and many of 
them have shown promising results in animals, giving 
chances to use them in humans [16]. At present, there 
are 477 clinical trials underway using EVs in different 
pathologies according to https://clinicaltrials.gov. 
We have summarized a portion of the clinical trials 
related to EVs in Table 1. 
The biogenesis of Extracellular Vesicles 
The biogenesis of EVs is similar but not exactly 
the same [9]. Exosomes are the smallest particles and 
are mainly composed of ceramide, a lipid produced 
from sphingosine [1]. Exosomes are formed 
intracellularly via endocytic invagination (early and 
late endosomes) and are released into a structure 
known as the multivesicular body (MVB), resulting in 
the progressive accumulation of intraluminal vesicles 
(ILVs) [5]. The MVB can undergo lysosome 
acidification and destruction or fusion with the 
plasma membrane, releasing its cargo of exosomes a 
mechanism regulated by Rab GTPases proteins [17, 
18]. Endosomal sorting complexes required for 
transport (ESCRT) is a mechanism of ILVs or MVB 
production [19]. ESCRT is a protein complex located 
on the cytoplasmic side of the endosome; its main 
function is to sort cell components into ILVs, forming 
the precursor of the exosomes. ESCRT contains four 
main complexes (ESCRT-0, I, II, III) and accessory 
proteins (such as vacuolar protein sorting 4, VPS4; 
vesicle trafficking 1, VTA1; ALG-2 interacting protein 
X, ALIX), all involved in exosomes biogenesis [20]. 
The ESCRT complex functions in a certain order. First, 
ESCRT-0 and ESCRT-I limit the ubiquitinated 
transmembrane cargo subunits to the micro-domains 
of MVE or ILVs, while causing deformation of the 
membrane structure, ESCRT-II is then used to recruit 
ESCRT-III for the budding and scission of this 
micro-domain [21, 22]. The classical ESCRT pathway 
interacts with syntenin and the ESCRT accessory 
protein ALIX, and bridges the ESCRT-III subunit 
VPS32, ultimately performing the scission function of 
the vesicles to form a closed vesicle [21]. The protein 
of the tetraspanin family is involved in the sorting of 
vesicle contents [21]. 
Microvesicles are the EVs class that has been the 
least studied and thus far we know very little about 
their biogenesis. They are usually larger than 
exosomes, depending on the cell type [1]. MVs are 
released by the direct budding or protrusion of the 
plasma membrane. They typically originate at the 
plasma membrane in the region called lipid rafts, 
which are membrane domains rich in cholesterol and 
glycosphingolipids [23]. The formation of MVs 
primarily involves membrane components and the 
cytoskeleton [9]. Moreover, during MVs formation 
there is externalization of the phospholipid 
phosphatidylserine (PS) [24], which normally resides 
exclusively in the inner layer of the plasma membrane 
[18].
 
Table 1. Clinical trials related to EVs. 
Condition or disease Origen of EVs Type of EVs Phase  NCT number 
Type1 Diabetes Mellitus Type2 Diabetes Islet Cell Transplantation Blood EVs ND NCT03106246 
Smoker Human broncho alveolar lavages EVs ND NCT03608293 
Blood Coagulation Disorders Bone marrow EVs ND NCT00086476 
Bronchopulmonary Dysplasia Bone marrow mesenchymal stem cell EVs Phase 1 NCT03857841 
Coronary Artery Disease Ischaemic Heart Disease Angina Pectoris Blood EVs ND NCT03674255 
Cancer Blood EVs ND NCT03262311 
Cerebrovascular Disorders Mesenchymal stem cell Exosomes  Phase 2 NCT03384433 
Ulcer Plasma Exosomes  Phase 1 NCT02565264 
Pancreatic Cancer Venous blood Exosomes  ND NCT03821909 
Colon Cancer Plant Exosomes  Phase 1 NCT01294072 
Sarcoma Blood Exosomes  ND NCT03800121 
Lymphoma Blood Exosomes  ND NCT03985696 
Cirrhosis Hepatocyte MVs ND NCT03837444 









Table 2. Composition of exosomes and microvesicles. 
Composition Exosomes Microvesicles 
Proteins MVB formation: ALIX, TSG101; Tetraspanins: CD9, CD63, CD81,CD82; 
Membrane transport and fusion: annexins, flotillins, GTPases; 
Adhesion: integrins; Antigen presentation: MHC class molecules; Heat 
shock proteins: HSC70, HSP90; Adaptor protein: Syntenin-1 
Matrix metalloproteinases; Tetraspanins: CD9, CD63; 
Glycoproteins: GPIb, GPIIb-IIIa, P-selectin; Integrins: Mac-1; 
Receptors: EGFRvIII; Cytoskeletal components: β-actin and 
α-actinin-4; Antigen presentation: MHC class molecules; 
Heat shock proteins: HSC70, HSP90 
Lipids Ceramide; Cholesterol; Phosphatidylserine; Sphingolipids Phosphatidylcholine; Sphingomyelin; 
Phosphatidylethanolamine; Lysophospholipids 
Nucleic acids mRNA; miRNA; Non-coding RNA; DNA mRNA; miRNA; Non-coding RNA; DNA 
 
Table 3. The potential protein markers of exosomes and microvesicles. 
 Exosomes Microvesicles 
Markers ALIX; TSG101; CD81; Syntenin-1; ADAM 10; EHD-4; Annexin XI Actinin-4; GP96; Mitofilin 
Shared markers Hsc70; Hsp90; Flotillin-1; Annexin II; MHC I; MHC II; CD9; CD63; Actin; Ezrin; Moesin 
 
 
Currently, no protein markers have been 
identified for distinguishing exosomes and MVs 
clearly. However, it has been extensively 
demonstrated that exosomes fractions are enriched by 
Alix, tumor susceptibility gene 101 (TSG101), CD81, 
and syntenin-1 proteins, whereas MVs fractions are 
enriched by integrins, metalloproteinases, and high 
levels of PS exposed to the outer membrane leaflet [2, 
25]. Hence, the following two tables summarize the 
differences in composition and potential protein 
markers for different classes of EVs. Table 3 is based 
on the work of Kowal J et al., which combines 
gradient centrifugation with iodixanol gradients to 
separate different sizes of EVs (light sEV, dense sEV, 
large EVs) and perform western blot (WB) detection 
[26]. Dissimilarly, Yusuke Y et al. performed WB 
detection on the total EVs obtained by 
ultracentrifugation of 9 different cells, analyzed the 
abundance of different kinds of conventional protein 
markers in the cell lysates and corresponding total 
EVs [27]. The results indicated that CD9 and CD81 are 
highly enriched in various EVs regardless of the 
corresponding protein abundance in parent cells. This 
slightly different result may be due to differences in 
the methods of extraction and comparison of WB, 
which also reminds us that various types of EVs need 
to be standardized protein markers. 
As for the release of EVs, a small fraction of EVs 
will be dissolved in the extracellular fluid with their 
cargoes, while most of them will interact with specific 
types of cells. This interaction is not random, but 
depends on the expression of some specific receptors 
on the cell surface, although these receptors are not 
fully identified [28, 29]. Moreover, the interaction of 
most EVs with this specific cell occurs not only near 
the release site, but also at regions far away from it. 
Through this interaction, a portion of EVs will bind 
directly to cell surface receptors, while others will 
activate receptors to trigger intracellular signaling, 
some that bind to the receptor and fuse with the target 
cell membrane, and then release the cargo into the 
cytoplasm; another portion of EVs will enter the cell 
by reverse extracellular fusion of the target cell 
membrane, this fusion occurring on the surface or 
being internalized by endocytosis or phagocytosis. 
Once endocytosed or phagocytosed, EVs can be 
degraded and their components captured by cells for 
their own physiology. When these cargoes are mixed 
with local molecules, they participate in the 
production of other EVs that are similarly released or 
fused to other cells. This process is defined as a 
recycling of intercellular communication [28-30]. 
EVs isolation and characterization methods 
In the last few years, many techniques for EVs 
isolation and characterization have been described in 
the literature, many of which, however, have not been 
well standardized [31]. To address this issue, the 
International Society for Extracellular Vesicles (ISEV) 
has published a paper on the minimal experimental 
requirements for definition of EVs and their function 
(MISEV) [32]. We list below the methods most widely 
used in EVs experimentation. 
Isolation: (1) Ultracentrifugation, including 
differential centrifugations for isolating different EVs 
fractions, is by far the primary isolation method in 
EVs application [31]. It removes cells and debris 
under low centrifugal force (300 ×g ~ 2000 ×g) and 
collects EVs under high centrifugal force (110000 ×g). 
The disadvantage is that the instrument is expensive, 
the extraction takes time and effort, and the purity is 
low. (2) Density gradient is used for isolating different 
fractions according to their different density. It is a 
more rigorous method than ultracentrifugation and is 
usually used to separate exosomes because of its high 
purity characteristics, but it cannot meet the 
requirements of large amount of samples [33]. (3) 
Co-precipitation technique relies on the ability of the 
customized polymer to co-precipitate EVs at lower 





centrifugation rates [34, 35]. This method easily causes 
co-precipitation of non-EVs components and greatly 
reduces the purity of EVs. Although commercial kits 
have been developed, they are still not suitable for 
large-scale use. (4) Size exclusion-chromatography 
(SEC) takes advantage of the principle of gel 
chromatography and the EVs are mainly purified by 
weight or size, it has a high yield but low specificity 
[34, 35]. Although these methods represent the most 
suitable ones proposed thus far, there is uncertainty 
about their application and efficacy in clinic, where 
the source of EVs samples is very often limited.  
The most commonly used method is 
ultracentrifugation, Ludwig AK et al. combined 
polyethylene glycol (PEG) co-precipitation and 
ultracentrifugation to obtain EVs from cell culture 
supernatants, which can obtain ideal EVs in large 
quantities without affecting the results of in vivo 
experiments[36]. This method also optimizes the 
shortcomings of PEG co-precipitation and has 
reproducibility and scalability, but the final product 
still contain several non-EV related molecules, which 
are less pure than size exclusion chromatography and 
sucrose density gradient centrifugation. At present, 
microfluidic filtering techniques are considered the 
most promising strategies for EVs separation in clinic 
based on their expandable flux, high degree of 
automation, and solid reproducibility [34, 37]. Liu C et 
al. introduced a method for EV purification by 
microfluidic filtering combined with droplet 
enzyme-linked immunosorbent assay (ELISA), which 
fills the gap in accurate quantification of EVs [38]. Wu 
et al. introduced a method based on the acoustic 
principle combined with microfluidic technology 
whereby it would become relatively simple to isolate 
EVs from whole blood, in a label-free and contact-free 
manner that would protect the peculiarities, 
structures and functions of isolated EVs [39]. Another 
novel technique for EVs purification proposed by 
Kabe et al. [40], consists of a high sensitivity and 
linearity method from human serum using the 
properties of magnetic nanobeads and optical disc 
technology. 
Characterization: WB remains by far the 
common used method for characterizing EVs; also, in 
this case, the ISEV has published guidelines for the 
identification of EVs, using antibody for proteins like 
CD63, CD9, CD81, TSG101, HSP70, Alix [9]. For 
studying EVs size and morphology, reliable methods 
are electron microscopy (EM) techniques such as 
transmission electron microscopy (TEM), scanning 
electron microscopy (SEM), Cryo-electron microscopy 
(Cryo-EM), and atomic force microscopy (AFM). 
Confocal fluorescence microscopy (CFM) is another 
advantageous technique for studying the interaction 
between EVs and cells [41-43]. This technique has 
resulted very convenient to study the internalization 
of EVs by recipient cells [42-46]. Mrinali et al. 
developed an innovative method that combines 
formalin with 1-ethyl-3-(3-dimethyl aminopropyl) 
carbodiimide (EDC) to improving EV imaging in situ. 
This approach avoids the traditional formalin-based 
technique, which may reverse cross-linkage due to 
temperature and allow EVs to escape from the tissue, 
resulting in a negative or low signal [47]. Therefore, 
this technology has dramatically improved EVs 
studies related to basic science, and perhaps, it will be 
used for clinical studies. Furthermore, Nanoparticle 
Tracking Analysis (NTA) and Tunable Resistive Pulse 
Sensing (TRPS) are common techniques for EVs 
quantification and size distribution [48]. NTA is able 
to track the scattering of individual vesicles over time, 
while TRPS is the change in the instantaneous current 
when the vesicles pass through the pores [49, 50]. 
According to the work of Akers JC et al, exosomes are 
more suitable for NTA, and MVs is more suitable for 
TRPS [51]. Flow Cytometry is also a widely use 
method for characterization and quantification [52], 
especially now that there is a new fluorescence 
activated cell sorting machine with a detection limit 
around 100 nm (Cytoflex) [34].  
EVs as therapy 
Our current knowledge on EVs provides 
opportunities for their use in therapy. The relevance 
of EVs as a therapeutic tool, already established in the 
last few years, is still growing and promising 
important developments for the near future. Many 
approaches have already been developed [5, 12, 35, 
53-55]. EVs act an important role in the therapeutic 
effect of MSCs and are therefore considered as a 
potential alternative to MSCs. Thus, MSC-derived 
EVs (MSC-EVs) would induce a regulatory response 
in the function of T-, B-, and monocyte-derived 
dendritic cells [56]. In the present work, MSC-EVs 
have been shown to possess immunomodulatory 
functions which promote B cell activation, induction 
of Breg and B cell proliferation was compared to that 
the whole MSCs [57]. Fujii et al., showed EVs derived 
from BM-NSCs have potential therapeutic effect on 
acute graft versus host disease (GVHD) and indicated 
the EVs probably inhibit the effector T cell induction 
and kept circulating naïve T cells [58]. However, EV 
usually does not treat as well as the cell itself, and its 
biological effects may be affected by the surrounding 
microenvironment [59]. In this case, Milad et al., 
found exosomes derived from MSCs stimulated by 
IFN-γ displayed a superior therapeutic effect 
compared with native exosomes. This study indicated 
that MSCs activated by IFN-γ, which promote 





IFNγ-Exo loaded more immunosuppressive cytokine 
indoleamine 2,3 -dioxygenase (IDO) resulted in 
peripheral blood mononuclear cells (PBMCs) 
proliferation disability. Therefore, this 
“pre-stimulation” of EVs greatly enhances its 
therapeutic effect and represents a new approach for 
treatment. 
The most intriguing aspect of EVs to have 
attracted the scientific interest is the possibility of 
customizing them “ad hoc” [13]. This means loading 
EVs with different functional molecules 
simultaneously [60], targeting EVs membrane for 
increasing tissue and cell targets [61]. We list here the 
most recent and promising studies published so far. 
Kamerkar et al. engineered exosomes (named in the 
paper iExosomes) to specifically target pancreatic 
cancer cell-associated KRAS mutant genes, delivering 
RNAi and CD47 on exosomes [55]. Directly specific 
targeting of KRAS was not possible to achieve before 
this study. On the other hand, Kumar et al. 
demonstrated an approach whereby EVs are 
encapsulated by a 10 nm thick protective film formed 
by a supramolecular complex of ferric ions and tannic 
acid to achieve non-essential EVs loss, and the 
protective film can be fused with other molecules as 
targeted delivery while the protective film is also 
subject to controlled degradation [62]. Longatti et al. 
published a method for specifically targeting 
exosomes membrane, with a single-chain variable 
fragment of antibody [63]. Recently, Jia G et al. 
demonstrated a method for treating glioma cells, 
using a click chemistry method to engineer exosomes 
with neuropilin-1 peptide and load them with 
curcumin [60]. Similarly, Tian et al. used a strategy for 
treating murine ischemia targeting exosomes with 
c(RGDyK) peptide [13]. 
However, there are still two problems that need 
to be solved: the methods for loading drugs into EVs 
cannot guarantee high loading efficiency [64], and, as 
a therapeutic medium, EVs cannot be targeted to the 
lesion area very well for therapeutic effects [65]. Thus, 
improving the EVs loading and delivering efficiency 
is one aspect that has been reconsidered, due to a 
discrepancy in the published protocol and data 
reproducibility [66]. Piffoux et al. published a method 
for loading EVs using liposomes and showed 
impressive results [67]. However, the efficacy of this 
protocol has not been confirmed.  
In the diagnosis and treatment of 
graft-versus-host disease (GVHD), the application of 
EVs has made more advancement. The EVs isolated 
from patient serum contains three miRNAs (miR-423, 
miR-199, miR-93), which may be related to the 
incidence and severity of GVHD [68]; and the 
expression of CD146, CD31, and CD140-α on EVs 
surface, is also closely related to the onset of the 
disease [69]. Traditional MSCs therapy after 
replacement with EVs for GVHD also showed ideal 
results, suggesting that MSCs-derived EVs are 
potential for cell-free therapy for GVHD [58, 70]. 
Kordelas L et al. used MSCs-derived EVs instead of 
MSCs in the patient with GVHD, and the promising 
results were obtained. MSCs-derived EVs provide a 
potentially viable method for refractory GVHD [71]. 
In other diseases, such as cancer, EVs also bring 
new opportunities for treatment, prevention or 
diagnosis. Some studies have found that proteins or 
nucleic acid components in EVs can inhibit tumor 
development [72], which may be a direct influence or 
through antigen presentation to immune cells. For 
example, DCs loaded with exosomes and alpha- 
galactosylceramide can significantly improve the 
tumor microenvironment of rats bearing gliomas and 
increase the median survival of rats [73]. In contrast, 
hepatocellular carcinoma-derived exosomes miR-21 
are thought to convert normal hepatic stellate cells to 
cancer-associated fibroblasts, thereby promoting 
tumor progression, which may provide new targets 
for the prevention and treatment of liver cancer [74]. 
The latest evidence suggests that the ability of EVs to 
tissue regeneration is equally astonishing. Human 
perivascular stem cell-derived EVs can mediate bone 
repair [75], and endothelial cell-derived exosomes can 
induce angiogenesis in ischemic myocardium [75], 
MSCs-derived EVs are important mediators of 
cartilage repair, which will have great application 
prospects as a therapeutic drug for cartilage 
regeneration and osteoarthritis [76]. 
Extracellular vesicles as biomarkers of 
autoimmune disease 
In the CNS, EVs have been observed in the 
cerebrospinal fluid, indicating their involvement in 
many autoimmune diseases, such as multiple 
sclerosis (MS) [77] and neuromyelitis optica [78]. They 
may play important roles in several biological 
processes such as cell-to-cell communication, immune 
system response, and nerve degeneration [79-81]. In 
MS, Verderio et al. showed that the number of 
myeloid EVs was enhanced. These myeloid-derived 
EVs were considered as diseases marker which 
separation from plasma and can be used to monitor 
disease progress [77, 82]. Similar works were also 
proved from plasma and serum and indicated EVs 
could provide useful information for disease 
diagnosis. However, serum has been questioned as a 
biomarker recently. The main comment is that 
PS-positive MVs in serum are consumed during the 
promotion of coagulation, and the remaining MVs do 
not reflect overall MVs levels; platelets also release 





MVs after activation in coagulation; what’s more, the 
presence of thrombin will also influence MVs surface 
proteins [83]. In summary, plasma rather than serum 
can lead to more convincing results [84]. 
Urine is another biological fluid commonly used 
for new biomarkers assess due to the noninvasive 
collection approach. Recently, the composition of 
exosomal miRNA was determined by deep 
sequencing and several stable expression miRNA 
were confirmed as biomarkers, which has verified the 
notion of urinary exosomes as a stable source of 
miRNA biomarkers for renal fibrosis [85]. Thus, EVs 
may be a novel biomarker that will soon replace 
biopsies.  
There is also evidence that miRNA production 
and transport are associated with autoimmune 
diseases, especially MS [86]. EVs contain a large 
amount of miRNA, which is the main carrier of 
circulating miRNAs [86], and the EVs content in 
patients' blood is also different from that of healthy 
controls [87]. This thus demonstrates that miRNAs in 
EVs are a potential biomarker for the diagnosis of MS. 
At the same time, it also sets forth requirements for 
the standardization of miRNA collection methods. 
Recently, the results of sequencing the total 
circulating exosomes transcriptome in patients with 
relapsing-remitting MS compared with healthy 
controls also confirmed that exosomal miRNA is very 
helpful as a biomarker for patients with MS [88]. In 
the table below, we summarize some of the recent 
studies on EVs as biomarkers in autoimmune 
diseases. 
EVs play an important role in autoantigen 
presentation and T cell modulation 
Given that EVs express peptide-MHC 
complexes, they may present antigens and activate 
immune cell-response [16]. EVs, in particular, 
exosomes, have been investigated in antigen 
presentation. Exosomes released by antigen- 
presenting cells (APC) may express class I and II 
MHC molecules and co-stimulation molecules and 
thus, theoretically, activate CD8+ and CD4+ T 
lymphocytes [89]. There are three major mechanisms 
for EVs to participate in autoantigen presentation. 
EVs participate in autoantigen presentation process 
involved in autoimmunity is shown in Fig. 1. 
Firstly, exosomes might act indirectly from APCs 
uptaking/stimulation [90]. This mechanism appears 
more relevant for naïve T cell activation. Eventually, 
costimulatory molecules expressed by APCs provide 
a necessary second signal for activating T 
lymphocytes. 
Secondly, the exosomes can be internalized by 
APCs and then present antigen to the surface to form 
a MHC complex [91, 92]. Once internalized by the 
APCs, the complex peptide/MHC will be exposed to 
the membrane. Finally, this complex will be involved 




Figure 1. Roles of EVs in autoantigen presentation response. 





Table 4. EVs as a biomarker in autoimmune disease. 
EVs Origin Classification Components Change Disease Reference 
Serum Exosomes Circulating exosomes ↑ Systemic lupus erythematosus [147] 
Urine Exosomes miR-146a ↑ Systemic lupus erythematosus [148] 
Urine Exosomes miR-29c ↓ Lupus nephritis [85] 
Serum Exosomes  Total exosomes ↑ Non-obese diabetes [149] 
CSF Microvesicles Total microvesicles ↑ Multiple sclerosis [77] 
Serum Exosomes  miRNA ↓ Multiple sclerosis [88] 
Serum Exosomes  Hotair ↑ Rheumatoid arthritis [150] 
Synovial fluid EVs miR-155 ↑ Rheumatoid arthritis [115] 
Saliva Exosomes miRNA / Sjögren's syndrome [151] 
Eosinophils Exosomes Total exosomes ↑ Asthma [152] 




Microparticles Total microparticles ↑ Multiple sclerosis [87] 
Serum Exosomes Myelin protein ↑ Multiple sclerosis [154] 
Urine  Microparticles Total microparticles ↑ Type 1 Diabetes [155] 
autoantigen presentation response. 
 
 
Thirdly, the study of the immunostimulatory 
capacity of APC-derived EVs is still a matter of 
debate. Some groups have shown that EVs can 
directly activate T cells [93], while others have shown 
that EV-dependent T cells stimulation is not enough 
and still requires APCs participation [94]. 
There are few studies on EVs release in T cell 
immune regulation mechanisms, but some reports 
have demonstrated its importance. It is noteworthy 
that regulatory T cells (Treg)-derived EVs could 
promote other T cells polarized to the Treg phenotype 
[95]. In addition, Treg effectively exocytosed 
immunosuppressive EVs that suppressed IFN-γ 
production and the proliferation of Th1 cells [96]. 
Similarly, EVs from endothelial cells possess the 
modulation ability which blocks T cells activation and 
alleviate chronic inflammation in tissue [97]. In this 
case, via the transfer of anti-inflammatory miRNAs, 
MSCs release immunosuppressive exosomes, which 
are actually used to treat autoimmunity disease in 
clinical [98, 99].  
The application of extracellular vesicles in 
autoimmune diseases 
Multiple Sclerosis (MS) 
MS and its animal model experimental 
autoimmune encephalomyelitis (EAE) is the most 
common inflammatory demyelinating disease caused 
by autoimmune-activated immune cells in the CNS 
[100, 101]. It has been reported that EVs can penetrate 
the blood-brain barrier (BBB) and contribute to brain 
antigens spreading to the periphery [102]. And the 
injection of microglia-derived EVs into the CNS of 
EAE mice enhanced inflammation and exaggerated 
disease [77]. Moreover, mice with an impaired ability 
to secrete EVs were resistant to EAE [77]. Therefore, 
these data indicate that EVs are involved in EAE 
mechanisms. Based on the EVs roles in EAE and MS, 
some groups developed treatment strategies that 
employed the function of exosomes. Exosomes 
(IFNγ-Exo) produced by IFNγ-stimulated MSCs have 
shown a good therapeutic effect on EAE [103]. These 
data provided evidence that MSCs-derived exosomes 
can be used as cell-free therapies for autoimmune and 
central nervous system diseases. The use of EVs 
derived from overexpression of TGF-β1 dendritic cells 
to EAE showed that Th1 and Th17 differentiation was 
inhibited and promoted Treg production, which led to 
diminished expression of EAE [104]. Casella G. et al. 
designed a mouse microglial cell line that releases a 
large amount of engineered EVs containing 
anti-inflammatory cytokine IL-4, after injection, the 
clinical score of EAE is significantly reduced [15]. 
Also, Zhuang et al. delivered curcumin-loaded 
exosomes through a nasal route to mice with 
lipopolysaccharide (LPS)-induced encephalitis and 
reduced neuroinflammation by targeting microglia 
[14]. In other similar LPS-induced inflammatory 
demyelinating models, curcumin is also encapsulated 
by exosomes, playing a role in enhancing 
anti-inflammatory activity [33]. In short, regardless of 
small-molecule chemical drugs, nucleotide drugs or 
protein drugs, as a drug delivery system, EVs have 
shown great potential for application in modern 
medicine. Furthermore, Pusic A. D. et al. implied 
exosomes released from bone marrow-derived 
dendritic cells as a therapeutic medium that 
supported the maturation of oligodendrocytes [105]. 
Dendritic cell-derived exosomes stimulated by low 
levels of pro-inflammatory factors IFN-γ contain 
higher levels of miR-219, which is vital for 
oligodendrocyte precursor cells (OPCs) 
differentiation; meanwhile, these exosomes are 
proved increase mature oligodendrocytes and 
recovery the destroyed myelin in vivo. Thus, exosomes 





might not only exacerbate inflammation during EAE 
but may also induce myelin regeneration.  
Rheumatoid Arthritis (RA) 
RA is an autoimmune disease in which the 
immune system reacts against the body’s cells and 
tissues. Generally, synoviocytes-derived exosomes, in 
inflammatory conditions like RA, stimulate 
surrounding cells to secrete inflammatory mediators 
for damaging cartilage [106]. It has been shown that 
the use of exosomes derived from IL-10 treated- 
dendritic cells, induced amelioration of RA severity 
[54]. IL-1β-stimulated fibroblast-like synoviocytes- 
derived EVs promoted osteoarthritic changes in 
chondrocytes [107]. In RA models, EVs have exhibited 
immunological abilities to induce apoptosis, 
presenting antigen to T cells, and causing extracellular 
damage [108]. All these pieces of evidence have 
contributed to propose synovium-derived EVs as 
possible biomarkers for RA [109, 110]; indeed, they 
might predict disease stage and, potentially, become 
relevant for building new and more effective 
therapeutic approaches.  
The pathogenesis of RA may be related to the 
communication of EVs cell-to-cell, which involves 
many complex processes such as antigen presentation 
and formation of immune complexes [111], 
inflammation [112, 113], destruction of extracellular 
matrix [114], delivery of miRNAs [115, 116]. Withrow 
J et al. and Fu H et al. reviewed in detail the research 
progress of EVs in these aspects [117, 118]. It can be 
concluded that EV mediates crosstalk between 
immune cells, synoviocytes, endothelial cells, and 
chondrocytes, thus affecting various processes of RA. 
These efforts may reveal the pathogenesis of RA, 
provide new insights into the targeted treatment of 
RA, and new treatment opportunities, as well as 
treatment strategies, may be discovered. 
Type 1 diabetes (T1D) 
T1D, also called diabetes mellitus type 1, is a 
form of diabetes mellitus in which pancreas fails to 
produce insulin. T1D is primarily a childhood 
associated autoimmune disease characterized by the 
destruction of insulin-producing β cells in the 
pancreatic islets of Langerhans [119]. Recent work 
showed that EVs may be involved in the pathogenesis 
of T1D playing a role in the presentation of 
autoantigen peptides from insulin-producing β cells. 
For example, T lymphocytes release exosomes 
containing specific microRNAs (for example, 
miR-142-3p, miR-142-5p, and miR-155) that transfer 
microRNAs to rodent and human pancreatic β cells, 
these microRNAs triggers the expression of 
chemokines in pancreatic β cells to promote apoptosis 
and result in insulin secretion disorders [120]. 
Exosomes also have shown potential as a therapeutic 
agent in treating T1D. In particular, exosomes from 
human urine-derived stem cells can prevent kidney 
injury in T1D rats by the transfer of growth factors, 
transforming growth factor-β1, angiogenin and bone 
morphogenetic protein-7 [121]. Interestingly, studies 
of MSCs have consistently shown that MSCs can 
inhibit autoimmunity in T1D [122, 123]. More detailed 
research data later indicated the positive effect of EVs 
on these two autoimmune diseases [124]. 
MSC-derived EVs not only inhibits Th1 and Th17 cells 
but increases the expression of immunosuppressive 
cytokine IL-10, thereby effectively preventing T1D 
disease development [124]. To further characterize of 
exosomes, their underlying mechanisms and 
relationship with different stages of the disease will 
furnish the understanding of the role of exosomes in 
the pathogenesis of T1D and their possible application 
as therapeutic tools. 
Antiphospholipid syndrome (APS) 
APS is an autoimmune disease that can cause 
venous or arterial thromboembolism or severe 
pregnancy mortality [125]. In the last two decades, 
researchers have believed that the APS pathogenesis 
may be related to persistent antiphospholipid 
antibodies (aPL) [126], and the main difficulty in 
elucidating the pathogenesis of APS is the 
heterogeneity of aPL [127]. There is strong evidence 
that EVs in patients with APS are indeed elevated. It is 
speculated that elevated EVs levels reflect the general 
state of vascular activation. It has been reported that 
EVs may stimulate thrombosis and promote vascular 
activation [128]. Analysis conducted in sera of 
patients affected by APS reported a significant 
increase in endothelial cell-derived microvesicles 
[129]. Limited experimental data indicate that aPL 
stimulation can induce endothelial cells to release 
specific EVs, unlike normal types, which contain IL-1β 
and specific miRNA molecules. Thus, with the spread 
of such EVs, the unstimulated endothelial cell was 
activated by an autocrine or paracrine manner [130]. 
In the APS condition, EVs have shown to induce the 
development of thrombosis through several 
mechanisms. For example, microvesicles express a 
high level of phosphatidylserine [131], and this might 
facilitate the assembly of calcium-dependent 
coagulation complexes and supports thrombin 
generation. Further, EVs are, usually, enriched of 
tissue factors and may directly support procoagulant 
activity [132]. Recent evidence demonstrated that 
endothelial microvesicles can interact with blood 
monocytes and stimulate procoagulant activity [133].  





Systemic lupus erythematosus (SLE) 
SLE is a chronic systemic autoimmune disease 
that influences various organs and systems. SLE is 
featured by elevated levels of pathogenic 
autoantibodies, resulting in deposition of immune 
complexes that cause damage to multiple systems and 
organs [134, 135]. Several studies reported the 
defective of apoptosis activity in SLE, leading to the 
development of autoimmunity [136]. Moreover, SLE 
patients exhibit an increased level of IgG-MPs in 
plasma compared to controls and it correlates to 
dsDNA antibodies [137]. Recent evidence suggests 
that apoptosis-derived membrane vesicles from the 
serum of SLE patients may activate cyclic guanosine 
monophosphate (GMP)-AMP synthase (cGAS) and 
stimulator of interferon genes (STING) pathway to 
induce the production of IFN-I [138]. It is suggested 
that blocking the cGAS-STING pathway or inhibiting 
the secretion of apoptosis-derived membrane vesicles 
may be a promising therapeutic target for SLE. On the 
other hand, MSCs infusions technology has been used 
to treat a variety of diseases. Liu's team showed that 
MSCs infusions can improve bone loss in 
Fas-deficient MRL/lpr mice and restore the function 
of bone marrow-derived MSCs, the mechanism is that 
MSCs infusions can down-regulate the intracellular 
level of miR-29b by reusing Fas from MSCs 
infusions-derived exosomes, thereby restoring the 
hypomethylation of the Notch1 promoter in SLE 
patients, suggesting that exosomes may have clinical 
therapeutic value in saving SLE secondary 
osteoporosis [139].  
Hashimoto thyroiditis (HT) 
HT is a common autoimmune disease with an 
annual incidence rate of about 1 per 1,000 people, 
mainly affecting women [140]. The pathogenesis is 
complex and unknown. Etiology divides HT into 
primary and secondary forms [141]. The pathological 
features of HT are mainly infiltration of hematopoietic 
monocytes (mainly lymphocytes), destroying thyroid 
cells, causing thyroid enlargement, fibrosis or other 
variants [142-144]. Then clinical manifestations of 
thyroid function decline or even loss [145], causing 
abnormalities in the gastrointestinal system, 
cardiovascular system, lung system, hematopoietic 
system, and nervous system [141]. The current 
research status still cannot explain the pathogenesis of 
HT, and a recent work discussed whether circulating 
exosomes participate in the inflammatory response of 
HT. By detecting exosomes in the serum of patients, it 
is indicated that these exosomes present antigen to 
activate DCs, after activation, it leads to an imbalance 
of CD4+ T cell differentiation, may induce HT, or will 




Figure 2. The application of extracellular vesicles in autoimmune diseases. 
  





In short, the existence of EVs is not only involved 
in the development of many autoimmune diseases but 
also participated in the treatment of these diseases as 
a therapeutic intermediary. We have summarized 
kinds of “Good” EVs that can participate in the 
treatment and “Bad” EVs that promote the 
development of the disease, shown in Fig. 2. 
Conclusion 
Research on EVs has been ardent since 2007 and 
has displayed unique advantages in various fields. 
EVs possess subcellular structures, which load and 
may deliver a variety of molecules that participate in 
many physiological processes. These pleiotropic 
effects may represent a greater breakthrough in the 
field of autoimmune diseases. However, the current 
problem to be solved is the standardization of the 
extraction and purification methods of EVs and the 
more accurate and effective quantification of the 
quantity or concentration of EVs. The characterization 
of EVs has been plaguing researchers, and the existing 
approaches are more or less flawed. With emerging 
technologies that can better solve this problem, 
spending more efforts to determine their origin 
characteristics, and the pathogenicity role of EVs may 
pave the way for new diagnostic methods. Given the 
various advantages of EVs and the current research 
results, we hope that EVs can also play a paramount 
role in autoimmune diseases, for example, as a carrier 
of therapeutic drugs or as a means of diagnosing 
diseases. This review retrospects the development, 
characterization, and biogenic derivation of EVs, as 
well as recent research achievements on autoimmune 
diseases. It is intended to provide basic ideas and 
information for scholars who have entered the field. 
Acknowledgments 
We thank Katherine Regan for editorial 
assistance. We apologize to all colleagues whose work 
could not be cited as a result of space limitations. 
Funding 
This study was supported by the Chinese 
National Natural Science Foundation (Grant 
Nos.31970771, 81771345), the Natural Science 
Foundation of Shaanxi Province, China (Grant 
Nos.2018JQ8033, 2018JZ3001, 2019KJXX-022), the 
Fundamental Research Funds for the Central 
Universities (Grant Nos. GK201903062, GK20182010, 
GK201701009, 2018CSLZ018), the Open Fund 
of Shanxi Key Laboratory of Inflammatory 
Neurodegenerative Diseases, Shanxi Datong 
University (Grant Nos.KF2019006, KF2019001). 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and 
friends. The Journal of cell biology. 2013; 200: 373-83. 
2. Kalra H, Drummen GP, Mathivanan S. Focus on Extracellular Vesicles: 
Introducing the Next Small Big Thing. International journal of molecular 
sciences. 2016; 17: 170. 
3. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation 
during reticulocyte maturation. Association of plasma membrane activities 
with released vesicles (exosomes). The Journal of biological chemistry. 1987; 
262: 9412-20. 
4. Harding CV, Heuser JE, Stahl PD. Exosomes: looking back three decades and 
into the future. The Journal of cell biology. 2013; 200: 367-71. 
5. Barile L, Vassalli G. Exosomes: Therapy delivery tools and biomarkers of 
diseases. Pharmacology & therapeutics. 2017; 174: 63-78. 
6. Morrison TJ, Jackson MV, Cunningham EK, Kissenpfennig A, McAuley DF, 
O'Kane CM, et al. Mesenchymal Stromal Cells Modulate Macrophages in 
Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial 
Transfer. Am J Respir Crit Care Med. 2017; 196: 1275-86. 
7. Meldolesi J. Extracellular vesicles, news about their role in immune cells: 
physiology, pathology and diseases. Clinical and experimental immunology. 
2019; 196: 318-27. 
8. Munagala R, Aqil F, Jeyabalan J, Gupta RC. Bovine milk-derived exosomes for 
drug delivery. Cancer letters. 2016; 371: 48-61. 
9. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular 
interactions of exosomes and other extracellular vesicles. Annual review of cell 
and developmental biology. 2014; 30: 255-89. 
10. Vella LJ, Scicluna BJ. A rigorous method to enrich for exosomes from brain 
tissue. J Extracell Vesicles. 2017; 6: 1348885. 
11. Ohno S, Drummen GP, Kuroda M. Focus on Extracellular Vesicles: 
Development of Extracellular Vesicle-Based Therapeutic Systems. 
International journal of molecular sciences. 2016; 17: 172. 
12. Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery 
vehicles across biological membranes: current perspectives and future 
challenges. Acta pharmaceutica Sinica B. 2016; 6: 287-96. 
13. Tian T, Zhang HX, He CP, Fan S, Zhu YL, Qi C, et al. Surface functionalized 
exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. 
Biomaterials. 2018; 150: 137-49. 
14. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, et al. Treatment of 
brain inflammatory diseases by delivering exosome encapsulated 
anti-inflammatory drugs from the nasal region to the brain. Molecular therapy 
: the journal of the American Society of Gene Therapy. 2011; 19: 1769-79. 
15. Casella G, Colombo F, Finardi A, Descamps H, Ill-Raga G, Spinelli A, et al. 
Extracellular Vesicles Containing IL-4 Modulate Neuroinflammation in a 
Mouse Model of Multiple Sclerosis. Molecular Therapy. 2018; 26: 2107-18. 
16. Turpin D, Truchetet ME, Faustin B, Augusto JF, Contin-Bordes C, Brisson A, et 
al. Role of extracellular vesicles in autoimmune diseases. Autoimmunity 
reviews. 2016; 15: 174-83. 
17. Pfeffer SR. Two Rabs for exosome release. Nature cell biology. 2010; 12: 3-4. 
18. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. 
Trends in cell biology. 2009; 19: 43-51. 
19. Hurley JH. ESCRT complexes and the biogenesis of multivesicular bodies. 
Current opinion in cell biology. 2008; 20: 4-11. 
20. Hurley JH. The ESCRT complexes. Critical reviews in biochemistry and 
molecular biology. 2010; 45: 463-87. 
21. Henne WM, Buchkovich NJ, Emr SD. The ESCRT pathway. Developmental 
cell. 2011; 21: 77-91. 
22. Hurley JH, Hanson PI. Membrane budding and scission by the ESCRT 
machinery: it's all in the neck. Nature reviews Molecular cell biology. 2010; 11: 
556-66. 
23. Lorent JH, Levental I. Structural determinants of protein partitioning into 
ordered membrane domains and lipid rafts. Chemistry and physics of lipids. 
2015; 192: 23-32. 
24. Martin KR, Kantari-Mimoun C, Yin M, Pederzoli-Ribeil M, Angelot-Delettre F, 
Ceroi A, et al. Proteinase 3 Is a Phosphatidylserine-binding Protein That 
Affects the Production and Function of Microvesicles. The Journal of biological 
chemistry. 2016; 291: 10476-89. 
25. Keerthikumar S, Chisanga D, Ariyaratne D, Al Saffar H, Anand S, Zhao K, et 
al. ExoCarta: A Web-Based Compendium of Exosomal Cargo. Journal of 
molecular biology. 2016; 428: 688-92. 
26. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, et al. 
Proteomic comparison defines novel markers to characterize heterogeneous 
populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A. 2016; 
113: E968-77. 
27. Yoshioka Y, Konishi Y, Kosaka N, Katsuda T, Kato T, Ochiya T. Comparative 
marker analysis of extracellular vesicles in different human cancer types. J 
Extracell Vesicles. 2013; 20424. 





28. Meldolesi J. Exosomes and Ectosomes in Intercellular Communication. 
Current biology : CB. 2018; 28: R435-r44. 
29. Sedgwick AE, D'Souza-Schorey C. The biology of extracellular microvesicles. 
Traffic. 2018; 19: 319-27. 
30. Buzas EI, Toth EA, Sodar BW, Szabo-Taylor KE. Molecular interactions at the 
surface of extracellular vesicles. Seminars in immunopathology. 2018; 40: 
453-64. 
31. Gardiner C, Di Vizio D, Sahoo S, Thery C, Witwer KW, Wauben M, et al. 
Techniques used for the isolation and characterization of extracellular vesicles: 
results of a worldwide survey. J Extracell Vesicles. 2016; 5: 32945. 
32. Witwer KW, Soekmadji C. Updating the MISEV minimal requirements for 
extracellular vesicle studies: building bridges to reproducibility. J Extracell 
Vesicles. 2017; 6: 1396823. 
33. Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, et al. A novel nanoparticle 
drug delivery system: the anti-inflammatory activity of curcumin is enhanced 
when encapsulated in exosomes. Molecular therapy : the journal of the 
American Society of Gene Therapy. 2010; 18: 1606-14. 
34. Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New 
Technologies for Analysis of Extracellular Vesicles. Chemical reviews. 2018; 
118: 1917-50. 
35. Kim MS, Haney MJ, Zhao Y, Yuan D, Deygen I, Klyachko NL, et al. 
Engineering macrophage-derived exosomes for targeted paclitaxel delivery to 
pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine : 
nanotechnology, biology, and medicine. 2018; 14: 195-204. 
36. Ludwig AK, De Miroschedji K, Doeppner TR, Borger V, Ruesing J, Rebmann 
V, et al. Precipitation with polyethylene glycol followed by washing and 
pelleting by ultracentrifugation enriches extracellular vesicles from tissue 
culture supernatants in small and large scales. J Extracell Vesicles. 2018; 7: 
1528109. 
37. Wunsch BH, Smith JT, Gifford SM, Wang C, Brink M, Bruce RL, et al. 
Nanoscale lateral displacement arrays for the separation of exosomes and 
colloids down to 20 nm. Nature nanotechnology. 2016; 11: 936-40. 
38. Liu C, Xu X, Li B, Situ B, Pan W, Hu Y, et al. Single-Exosome-Counting 
Immunoassays for Cancer Diagnostics. Nano Lett. 2018; 18: 4226-32. 
39. Wu M, Ouyang Y, Wang Z, Zhang R, Huang PH, Chen C, et al. Isolation of 
exosomes from whole blood by integrating acoustics and microfluidics. Proc 
Natl Acad Sci U S A. 2017; 114: 10584-9. 
40. Kabe Y, Suematsu M, Sakamoto S, Hirai M, Koike I, Hishiki T, et al. 
Development of a Highly Sensitive Device for Counting the Number of 
Disease-Specific Exosomes in Human Sera. Clinical chemistry. 2018; 64: 
1463-73. 
41. Liu ML, Williams KJ, Werth VP. Microvesicles in Autoimmune Diseases. 
Advances in clinical chemistry. 2016; 77: 125-75. 
42. Song Y, Zhang C, Zhang J, Jiao Z, Dong N, Wang G, et al. Localized injection of 
miRNA-21-enriched extracellular vesicles effectively restores cardiac function 
after myocardial infarction. Theranostics. 2019; 9: 2346-60. 
43. Mondal A, Ashiq KA, Phulpagar P, Singh DK, Shiras A. Effective 
Visualization and Easy Tracking of Extracellular Vesicles in Glioma Cells. 
Biological procedures online. 2019; 21: 4. 
44. Roberts-Dalton HD, Cocks A, Falcon-Perez JM, Sayers EJ, Webber JP, Watson 
P, et al. Fluorescence labelling of extracellular vesicles using a novel 
thiol-based strategy for quantitative analysis of cellular delivery and 
intracellular traffic. Nanoscale. 2017; 9: 13693-706. 
45. Lazaro-Ibanez E, Neuvonen M. Metastatic state of parent cells influences the 
uptake and functionality of prostate cancer cell-derived extracellular vesicles. J 
Extracell Vesicles. 2017; 6: 1354645. 
46. Paul D, Baena V, Ge S, Jiang X, Jellison ER, Kiprono T, et al. Appearance of 
claudin-5(+) leukocytes in the central nervous system during 
neuroinflammation: a novel role for endothelial-derived extracellular vesicles. 
Journal of neuroinflammation. 2016; 13: 292. 
47. Gupta MP, Tandalam S, Ostrager S, Lever AS, Fung AR, Hurley DD, et al. 
Non-reversible tissue fixation retains extracellular vesicles for in situ imaging. 
Nature methods. 2019; doi: 10.1038/s41592-019-0623-4. 
48. Maas SL, de Vrij J, van der Vlist EJ, Geragousian B, van Bloois L, 
Mastrobattista E, et al. Possibilities and limitations of current technologies for 
quantification of biological extracellular vesicles and synthetic mimics. Journal 
of controlled release : official journal of the Controlled Release Society. 2015; 
200: 87-96. 
49. Gardiner C, Ferreira YJ, Dragovic RA, Redman CW, Sargent IL. Extracellular 
vesicle sizing and enumeration by nanoparticle tracking analysis. J Extracell 
Vesicles. 2013; 2. doi:10.3402/jev.v2i0.19671 
50. Vogel R, Coumans FA, Maltesen RG, Böing AN, Bonnington KE, Broekman 
ML, et al. A standardized method to determine the concentration of 
extracellular vesicles using tunable resistive pulse sensing. J Extracell Vesicles. 
2016; 5: 31242. 
51. Akers JC, Ramakrishnan V, Nolan JP, Duggan E, Fu CC, Hochberg FH, et al. 
Comparative Analysis of Technologies for Quantifying Extracellular Vesicles 
(EVs) in Clinical Cerebrospinal Fluids (CSF). PloS one. 2016; 11: e0149866. 
52. Stoner SA, Duggan E, Condello D, Guerrero A, Turk JR, Narayanan PK, et al. 
High sensitivity flow cytometry of membrane vesicles. Cytometry Part A : the 
journal of the International Society for Analytical Cytology. 2016; 89: 196-206. 
53. Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery 
platform using engineered natural membrane vesicle exosomes for targeted 
tumor therapy. Biomaterials. 2014; 35: 2383-90. 
54. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, et al. Exosomes 
derived from IL-10-treated dendritic cells can suppress inflammation and 
collagen-induced arthritis. Journal of immunology (Baltimore, Md : 1950). 
2005; 174: 6440-8. 
55. Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, et al. 
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic 
cancer. Nature. 2017; 546: 498-503. 
56. Najar M, Bouhtit F, Melki R, Afif H, Hamal A, Fahmi H, et al. Mesenchymal 
Stromal Cell-Based Therapy: New Perspectives and Challenges. Journal of 
clinical medicine. 2019; 8. doi:10.3390/jcm8050626 
57. Carreras-Planella L, Monguio-Tortajada M, Borras FE, Franquesa M. 
Immunomodulatory Effect of MSC on B Cells Is Independent of Secreted 
Extracellular Vesicles. Frontiers in immunology. 2019; 10: 1288. 
58. Fujii S, Miura Y. Graft-Versus-Host Disease Amelioration by Human Bone 
Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is 
Associated with Peripheral Preservation of Naive T Cell Populations. Stem 
Cells. 2018; 36: 434-45. 
59. Burrello J, Monticone S, Gai C, Gomez Y, Kholia S, Camussi G. Stem 
Cell-Derived Extracellular Vesicles and Immune-Modulation. Frontiers in cell 
and developmental biology. 2016; 4: 83. 
60. Jia G, Han Y, An Y, Ding Y, He C, Wang X, et al. NRP-1 targeted and 
cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma 
in vitro and in vivo. Biomaterials. 2018; 178: 302-16. 
61. Vader P, Mol EA, Pasterkamp G, Schiffelers RM. Extracellular vesicles for 
drug delivery. Advanced drug delivery reviews. 2016; 106: 148-56. 
62. Kumar S, Michael IJ, Park J, Granick S, Cho YK. Cloaked Exosomes: 
Biocompatible, Durable, and Degradable Encapsulation. Small. 2018; 14: 
e1802052. 
63. Longatti A, Schindler C. High affinity single-chain variable fragments are 
specific and versatile targeting motifs for extracellular vesicles. Nanoscale. 
2018; 10: 14230-44. 
64. Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, et al. 
Exosomes as drug delivery vehicles for Parkinson's disease therapy. Journal of 
controlled release : official journal of the Controlled Release Society. 2015; 207: 
18-30. 
65. Smyth T, Kullberg M, Malik N, Smith-Jones P, Graner MW, Anchordoquy TJ. 
Biodistribution and delivery efficiency of unmodified tumor-derived 
exosomes. Journal of controlled release : official journal of the Controlled 
Release Society. 2015; 199: 145-55. 
66. Phinney DG, Pittenger MF. Concise Review: MSC-Derived Exosomes for 
Cell-Free Therapy. Stem Cells. 2017; 35: 851-8. 
67. Piffoux M, Silva AKA, Wilhelm C. Modification of Extracellular Vesicles by 
Fusion with Liposomes for the Design of Personalized Biogenic Drug Delivery 
Systems. ACS Nano. 2018; 12: 6830-42. 
68. Crossland RE, Norden J, Kralj Juric M, Pearce KF, Lendrem C, Bibby LA, et al. 
Serum and Extracellular Vesicle MicroRNAs miR-423, miR-199, and miR-93* 
As Biomarkers for Acute Graft-versus-Host Disease. Frontiers in immunology. 
2017; 8: 1446. 
69. Lia G, Brunello L, Bruno S, Carpanetto A, Omede P, Festuccia M, et al. 
Extracellular vesicles as potential biomarkers of acute graft-vs-host disease. 
Leukemia. 2018; 32: 765-73. 
70. Wang L, Gu Z, Zhao X, Yang N, Wang F, Deng A, et al. Extracellular Vesicles 
Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells 
Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model 
of Allogeneic Hematopoietic Stem Cell Transplantation. Stem cells and 
development. 2016; 25: 1874-83. 
71. Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, et al. 
MSC-derived exosomes: a novel tool to treat therapy-refractory 
graft-versus-host disease. Leukemia. 2014; 28: 970-3. 
72. Chulpanova D, Kitaeva K, James V, Rizvanov A, Solovyeva V. Therapeutic 
Prospects of Extracellular Vesicles in Cancer Treatment. Frontiers in 
immunology. 2018; 9: 1534. 
73. Yang DZ, Liang J, Zhang F, Yao HB, Shu Y. Clinical effect of montelukast 
sodium combined with inhaled corticosteroids in the treatment of OSAS 
children. Medicine. 2017; 96: e6628. 
74. Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J, et al. Hepatocellular 
carcinoma-derived exosomal miRNA-21 contributes to tumor progression by 
converting hepatocyte stellate cells to cancer-associated fibroblasts. Journal of 
experimental & clinical cancer research : CR. 2018; 37: 324. 
75. Xu J, Wang Y, Hsu C, Gao Y, Meyers C, Chang L, et al. Human perivascular 
stem cell-derived extracellular vesicles mediate bone repair. eLife. 2019; 8: 
undefined. doi:10.7554/eLife.48191 
76. Vonk L, Dooremalen Sv, Liv N, Klumperman J, Coffer P, Saris D, et al. 
Mesenchymal Stromal/stem Cell-derived Extracellular Vesicles Promote 
Human Cartilage Regeneration. Theranostics. 2018; 8: 906-20. 
77. Verderio C, Muzio L, Turola E, Bergami A, Novellino L, Ruffini F, et al. 
Myeloid microvesicles are a marker and therapeutic target for 
neuroinflammation. Annals of neurology. 2012; 72: 610-24. 
78. Lee J, McKinney KQ, Pavlopoulos AJ, Han MH, Kim SH, Kim HJ, et al. 
Exosomal proteome analysis of cerebrospinal fluid detects biosignatures of 
neuromyelitis optica and multiple sclerosis. Clinica chimica acta; international 
journal of clinical chemistry. 2016; 462: 118-26. 
79. Tominaga N, Yoshioka Y, Ochiya T. A novel platform for cancer therapy using 
extracellular vesicles. Advanced drug delivery reviews. 2015; 95: 50-5. 





80. Robbins PD, Morelli AE. Regulation of immune responses by extracellular 
vesicles. Nature reviews Immunology. 2014; 14: 195-208. 
81. Loov C, Scherzer CR, Hyman BT, Breakefield XO, Ingelsson M. 
alpha-Synuclein in Extracellular Vesicles: Functional Implications and 
Diagnostic Opportunities. Cellular and molecular neurobiology. 2016; 36: 
437-48. 
82. Huttner HB, Corbeil D, Thirmeyer C, Coras R, Kohrmann M, Mauer C, et al. 
Increased membrane shedding--indicated by an elevation of CD133-enriched 
membrane particles--into the CSF in partial epilepsy. Epilepsy research. 2012; 
99: 101-6. 
83. Liu ML, Werth VP, Williams KJ. Blood plasma versus serum: which is right for 
sampling circulating membrane microvesicles in human subjects? Annals of 
the rheumatic diseases. 2019. doi:10.1136/annrheumdis-2019-215505 
84. Kato Y, Park J, Takamatsu H, Kumanogoh A. Response to: 'Blood plasma 
versus serum: which is right for sampling circulating membrane microvesicles 
in human subjects?' by Liu et al. Annals of the rheumatic diseases. 2019. 
doi:10.1136/annrheumdis-2019-215540 
85. Sole C, Cortes-Hernandez J, Felip ML, Vidal M, Ordi-Ros J. miR-29c in urinary 
exosomes as predictor of early renal fibrosis in lupus nephritis. Nephrology, 
dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association. 2015; 30: 1488-96. 
86. Jagot F, Davoust N. Is It worth Considering Circulating microRNAs in 
Multiple Sclerosis? Frontiers in immunology. 2016; 7: 129. 
87. Saenz-Cuesta M, Irizar H, Castillo-Trivino T, Munoz-Culla M, 
Osorio-Querejeta I, Prada A, et al. Circulating microparticles reflect treatment 
effects and clinical status in multiple sclerosis. Biomarkers in medicine. 2014; 
8: 653-61. 
88. Selmaj I, Cichalewska M, Namiecinska M, Galazka G, Horzelski W, Selmaj 
KW, et al. Global exosome transcriptome profiling reveals biomarkers for 
multiple sclerosis. Annals of neurology. 2017; 81: 703-17. 
89. Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA, et al. Analysis 
of antigen presenting cell derived exosomes, based on immuno-magnetic 
isolation and flow cytometry. Journal of immunological methods. 2001; 247: 
163-74. 
90. Arima Y, Liu W, Takahashi Y, Nishikawa M, Takakura Y. Effects of 
localization of antigen proteins in antigen-loaded exosomes on efficiency of 
antigen presentation. Molecular pharmaceutics. 2019; 16: 2309-14. 
91. Leone DA, Rees AJ, Kain R. Dendritic cells and routing cargo into exosomes. 
Immunology & Cell Biology. 2018; 96: 683-93. 
92. Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB, Papworth GD, 
et al. Endocytosis, intracellular sorting, and processing of exosomes by 
dendritic cells. Blood. 2004; 104: 3257-66. 
93. Liu Q, Rojas-Canales DM, Divito SJ, Shufesky WJ, Stolz DB, Erdos G, et al. 
Donor dendritic cell-derived exosomes promote allograft-targeting immune 
response. The Journal of clinical investigation. 2016; 126: 2805-20. 
94. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S. Indirect 
activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nature 
immunology. 2002; 3: 1156-62. 
95. Aiello S, Rocchetta F, Longaretti L, Faravelli S, Todeschini M, Cassis L, et al. 
Extracellular vesicles derived from T regulatory cells suppress T cell 
proliferation and prolong allograft survival. Sci Rep. 2017; 7: 11518. 
96. Okoye IS, Coomes SM, Pelly VS, Czieso S, Papayannopoulos V, Tolmachova T, 
et al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress 
pathogenic T helper 1 cells. Immunity. 2014; 41: 89-103. 
97. Njock MS, Cheng HS, Dang LT, Nazari-Jahantigh M, Lau AC, Boudreau E, et 
al. Endothelial cells suppress monocyte activation through secretion of 
extracellular vesicles containing antiinflammatory microRNAs. Blood. 2015; 
125: 3202-12. 
98. Casado JG, Blazquez R, Vela FJ, Alvarez V, Tarazona R, Sanchez-Margallo FM. 
Mesenchymal Stem Cell-Derived Exosomes: Immunomodulatory Evaluation 
in an Antigen-Induced Synovitis Porcine Model. Frontiers in veterinary 
science. 2017; 4: 39. 
99. Pistoia V, Raffaghello L. Mesenchymal stromal cells and autoimmunity. 
International immunology. 2017; 29: 49-58. 
100. Zhang Y, Han JJ, Liang XY, Zhao L, Zhang F, Rasouli J, et al. miR-23b 
Suppresses Leukocyte Migration and Pathogenesis of Experimental 
Autoimmune Encephalomyelitis by Targeting CCL7. Molecular therapy : the 
journal of the American Society of Gene Therapy. 2018; 26: 582-92. 
101. Li X, Zhang Y, Yan Y, Ciric B, Ma CG, Chin J, et al. LINGO-1-Fc-Transduced 
Neural Stem Cells Are Effective Therapy for Chronic Stage Experimental 
Autoimmune Encephalomyelitis. Molecular neurobiology. 2017; 54: 4365-78. 
102. Selmaj I, Mycko MP, Raine CS, Selmaj KW. The role of exosomes in CNS 
inflammation and their involvement in multiple sclerosis. Journal of 
neuroimmunology. 2017; 306: 1-10. 
103. Riazifar M, Mohammadi MR. Stem Cell-Derived Exosomes as 
Nanotherapeutics for Autoimmune and Neurodegenerative Disorders. ACS 
Nano. 2019; 13: 6670-88. 
104. Yu L, Yang F, Jiang L, Chen Y, Wang K, Xu F, et al. Exosomes with 
membrane-associated TGF-beta1 from gene-modified dendritic cells inhibit 
murine EAE independently of MHC restriction. European journal of 
immunology. 2013; 43: 2461-72. 
105. Pusic AD, Pusic KM, Kraig RP. What are exosomes and how can they be used 
in multiple sclerosis therapy? Expert review of neurotherapeutics. 2014; 14: 
353-5. 
106. Lo Cicero A, Majkowska I, Nagase H, Di Liegro I, Troeberg L. Microvesicles 
shed by oligodendroglioma cells and rheumatoid synovial fibroblasts contain 
aggrecanase activity. Matrix biology : journal of the International Society for 
Matrix Biology. 2012; 31: 229-33. 
107. Kato T, Miyaki S, Ishitobi H, Nakamura Y, Nakasa T, Lotz MK, et al. Exosomes 
from IL-1beta stimulated synovial fibroblasts induce osteoarthritic changes in 
articular chondrocytes. Arthritis research & therapy. 2014; 16: R163. 
108. Zhang HG, Liu C, Su K, Yu S, Zhang L, Zhang S, et al. A membrane form of 
TNF-alpha presented by exosomes delays T cell activation-induced cell death. 
Journal of immunology (Baltimore, Md : 1950). 2006; 176: 7385-93. 
109. Skriner K, Adolph K, Jungblut PR, Burmester GR. Association of citrullinated 
proteins with synovial exosomes. Arthritis and rheumatism. 2006; 54: 3809-14. 
110. Sellam J, Proulle V, Jungel A, Ittah M, Miceli Richard C, Gottenberg JE, et al. 
Increased levels of circulating microparticles in primary Sjogren's syndrome, 
systemic lupus erythematosus and rheumatoid arthritis and relation with 
disease activity. Arthritis research & therapy. 2009; 11: R156. 
111. Cloutier N, Tan S, Boudreau LH, Cramb C, Subbaiah R, Lahey L, et al. The 
exposure of autoantigens by microparticles underlies the formation of potent 
inflammatory components: the microparticle-associated immune complexes. 
EMBO molecular medicine. 2013; 5: 235-49. 
112. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, et al. 
Platelets amplify inflammation in arthritis via collagen-dependent 
microparticle production. Science (New York, NY). 2010; 327: 580-3. 
113. Headland SE, Jones HR, Norling LV, Kim A, Souza PR, Corsiero E, et al. 
Neutrophil-derived microvesicles enter cartilage and protect the joint in 
inflammatory arthritis. Science translational medicine. 2015; 7: 315ra190. 
114. van Nieuwenhuijze AE, van de Loo FA, Walgreen B, Bennink M, Helsen M, 
van den Bersselaar L, et al. Complementary action of granulocyte macrophage 
colony-stimulating factor and interleukin-17A induces interleukin-23, receptor 
activator of nuclear factor-κB ligand, and matrix metalloproteinases and 
drives bone and cartilage pathology in experimental arthritis: rationale for 
combination therapy in rheumatoid arthritis. Arthritis research & therapy. 
2015; 17: 163. 
115. Kurowska-Stolarska M, Alivernini S, Ballantine LE, Asquith DL, Millar NL, 
Gilchrist DS, et al. MicroRNA-155 as a proinflammatory regulator in clinical 
and experimental arthritis. Proc Natl Acad Sci U S A. 2011; 108: 11193-8. 
116. Alexander M, Hu R, Runtsch MC, Kagele DA, Mosbruger TL, Tolmachova T, 
et al. Exosome-delivered microRNAs modulate the inflammatory response to 
endotoxin. Nature communications. 2015; 6: 7321. 
117. Withrow J, Murphy C, Liu Y, Hunter M, Fulzele S, Hamrick MW. Extracellular 
vesicles in the pathogenesis of rheumatoid arthritis and osteoarthritis. 
Arthritis research & therapy. 2016; 18: 286. 
118. Fu H, Hu D, Zhang L, Tang P. Role of extracellular vesicles in rheumatoid 
arthritis. Molecular immunology. 2018; 93: 125-32. 
119. Garcia-Contreras M, Brooks RW, Boccuzzi L, Robbins PD, Ricordi C. 
Exosomes as biomarkers and therapeutic tools for type 1 diabetes mellitus. 
European review for medical and pharmacological sciences. 2017; 21: 2940-56. 
120. Guay C, Kruit JK, Rome S, Menoud V, Mulder NL, Jurdzinski A, et al. 
Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic beta Cell 
Death and May Contribute to Type 1 Diabetes Development. Cell metabolism. 
2018; 29: 348-61. 
121. Jiang ZZ, Liu YM, Niu X, Yin JY, Hu B, Guo SC, et al. Exosomes secreted by 
human urine-derived stem cells could prevent kidney complications from 
type I diabetes in rats. Stem cell research & therapy. 2016; 7: 24. 
122. Kota DJ, Wiggins LL, Yoon N, Lee RH. TSG-6 produced by hMSCs delays the 
onset of autoimmune diabetes by suppressing Th1 development and 
enhancing tolerogenicity. Diabetes. 2013; 62: 2048-58. 
123. Ko JH, Lee HJ, Jeong HJ, Kim MK, Wee WR, Yoon SO, et al. Mesenchymal 
stem/stromal cells precondition lung monocytes/macrophages to produce 
tolerance against allo- and autoimmunity in the eye. Proc Natl Acad Sci U S A. 
2016; 113: 158-63. 
124. Shigemoto-Kuroda T, Oh J, Kim D, Jeong H, Park S, Lee H, et al. MSC-derived 
Extracellular Vesicles Attenuate Immune Responses in Two Autoimmune 
Murine Models: Type 1 Diabetes and Uveoretinitis. Stem cell reports. 2017; 8: 
1214-25. 
125. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. 
International consensus statement on an update of the classification criteria for 
definite antiphospholipid syndrome (APS). Journal of thrombosis and 
haemostasis : JTH. 2006; 4: 295-306. 
126. Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, 
et al. Effect of human IgG antiphospholipid antibodies on an in vivo 
thrombosis model in mice. Thrombosis and haemostasis. 1994; 71: 670-4. 
127. Lackner KJ, Muller-Calleja N. Pathogenesis of antiphospholipid syndrome: 
recent insights and emerging concepts. Expert review of clinical immunology. 
2018; 15: 199-209. 
128. Zara M, Guidetti GF, Camera M, Canobbio I, Amadio P, Torti M, et al. Biology 
and Role of Extracellular Vesicles (EVs) in the Pathogenesis of Thrombosis. 
International journal of molecular sciences. 2019; 20. doi:10.3390/ijms20112840 
129. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, et al. In vitro 
generation of endothelial microparticles and possible prothrombotic activity 
in patients with lupus anticoagulant. The Journal of clinical investigation. 
1999; 104: 93-102. 
130. Wu M, Barnard J, Kundu S, McCrae KR. A novel pathway of cellular 
activation mediated by antiphospholipid antibody-induced extracellular 
vesicles. Journal of thrombosis and haemostasis : JTH. 2015; 13: 1928-40. 





131. Leroyer AS, Anfosso F, Lacroix R, Sabatier F, Simoncini S, Njock SM, et al. 
Endothelial-derived microparticles: Biological conveyors at the crossroad of 
inflammation, thrombosis and angiogenesis. Thrombosis and haemostasis. 
2010; 104: 456-63. 
132. Thomas GM, Brill A, Mezouar S, Crescence L, Gallant M, Dubois C, et al. 
Tissue factor expressed by circulating cancer cell-derived microparticles 
drastically increases the incidence of deep vein thrombosis in mice. Journal of 
thrombosis and haemostasis : JTH. 2015; 13: 1310-9. 
133. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. 
Interaction of endothelial microparticles with monocytic cells in vitro induces 
tissue factor-dependent procoagulant activity. Blood. 2002; 99: 3962-70. 
134. Colasanti T, Maselli A, Conti F, Sanchez M, Alessandri C, Barbati C, et al. 
Autoantibodies to estrogen receptor alpha interfere with T lymphocyte 
homeostasis and are associated with disease activity in systemic lupus 
erythematosus. Arthritis and rheumatism. 2012; 64: 778-87. 
135. Al-Shobaili HA, Al Robaee AA, Alzolibani AA, Rasheed Z. Antibodies against 
4-hydroxy-2-nonenal modified epitopes recognized chromatin and its 
oxidized forms: role of chromatin, oxidized forms of chromatin and 
4-hydroxy-2-nonenal modified epitopes in the etiopathogenesis of SLE. 
Disease markers. 2012; 33: 19-34. 
136. Dieker J, Hilbrands L, Thielen A, Dijkman H, Berden JH, van der Vlag J. 
Enhanced activation of dendritic cells by autologous apoptotic microvesicles 
in MRL/lpr mice. Arthritis research & therapy. 2015; 17: 103. 
137. Nielsen CT, Ostergaard O, Stener L, Iversen LV, Truedsson L, Gullstrand B, et 
al. Increased IgG on cell-derived plasma microparticles in systemic lupus 
erythematosus is associated with autoantibodies and complement activation. 
Arthritis and rheumatism. 2012; 64: 1227-36. 
138. Kato Y, Park J, Takamatsu H, Konaka H, Aoki W, Aburaya S, et al. 
Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and 
enhance type I IFN production in systemic lupus erythematosus. Annals of the 
rheumatic diseases. 2018; 77: 1507-15. 
139. Liu S, Liu D, Chen C, Hamamura K, Moshaverinia A, Yang R, et al. MSC 
Transplantation Improves Osteopenia via Epigenetic Regulation of Notch 
Signaling in Lupus. Cell metabolism. 2015; 22: 606-18. 
140. McLeod DS, Cooper DS. The incidence and prevalence of thyroid 
autoimmunity. Endocrine. 2012; 42: 252-65. 
141. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and 
diagnostic criteria. Autoimmunity reviews. 2014; 13: 391-7. 
142. De Luca F, Santucci S, Corica D, Pitrolo E, Romeo M, Aversa T. Hashimoto's 
thyroiditis in childhood: presentation modes and evolution over time. Italian 
journal of pediatrics. 2013; 39: 8. 
143. Li Y, Bai Y, Liu Z, Ozaki T, Taniguchi E, Mori I, et al. Immunohistochemistry 
of IgG4 can help subclassify Hashimoto's autoimmune thyroiditis. Pathology 
international. 2009; 59: 636-41. 
144. Caturegli P, De Remigis A, Chuang K, Dembele M, Iwama A, Iwama S. 
Hashimoto's thyroiditis: celebrating the centennial through the lens of the 
Johns Hopkins hospital surgical pathology records. Thyroid : official journal of 
the American Thyroid Association. 2013; 23: 142-50. 
145. Vanderpump MP. The epidemiology of thyroid disease. British medical 
bulletin. 2011; 99: 39-51. 
146. Cui X, Liu Y, Wang S, Zhao N, Qin J, Li Y, et al. Circulating Exosomes Activate 
Dendritic Cells and Induce Unbalanced CD4+ T Cell Differentiation in 
Hashimoto Thyroiditis. The Journal of clinical endocrinology and metabolism. 
2019; 104: 4607-18. 
147. Lee JY, Park JK, Lee EY, Lee EB, Song YW. Circulating exosomes from patients 
with systemic lupus erythematosus induce an proinflammatory immune 
response. Arthritis research & therapy. 2016; 18: 264. 
148. Perez-Hernandez J, Forner MJ, Pinto C, Chaves FJ, Cortes R, Redon J. 
Increased Urinary Exosomal MicroRNAs in Patients with Systemic Lupus 
Erythematosus. PloS one. 2015; 10: e0138618. 
149. Rahman MJ, Regn D, Bashratyan R, Dai YD. Exosomes released by 
islet-derived mesenchymal stem cells trigger autoimmune responses in NOD 
mice. Diabetes. 2014; 63: 1008-20. 
150. Song J, Kim D, Han J, Kim Y, Lee M, Jin EJ. PBMC and exosome-derived 
Hotair is a critical regulator and potent marker for rheumatoid arthritis. 
Clinical and experimental medicine. 2015; 15: 121-6. 
151. Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, et al. 
Exosomes from human saliva as a source of microRNA biomarkers. Oral 
diseases. 2010; 16: 34-8. 
152. Mazzeo C, Canas JA, Zafra MP, Rojas Marco A, Fernandez-Nieto M, Sanz V, et 
al. Exosome secretion by eosinophils: A possible role in asthma pathogenesis. 
The Journal of allergy and clinical immunology. 2015; 135: 1603-13. 
153. Pieragostino D, Cicalini I, Lanuti P, Ercolino E, di Ioia M, Zucchelli M, et al. 
Enhanced release of acid sphingomyelinase-enriched exosomes generates a 
lipidomics signature in CSF of Multiple Sclerosis patients. Sci Rep. 2018; 8: 
3071. 
154. Galazka G, Mycko MP, Selmaj I, Raine CS, Selmaj KW. Multiple sclerosis: 
Serum-derived exosomes express myelin proteins. Multiple sclerosis. 2018; 24: 
449-58. 
155. Lytvyn Y, Xiao F, Kennedy CR, Perkins BA, Reich HN, Scholey JW, et al. 
Assessment of urinary microparticles in normotensive patients with type 1 
diabetes. Diabetologia. 2017; 60: 581-4. 
 
